Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FWS reduces minimum age requirement for ginseng export

This article was originally published in The Tan Sheet

Executive Summary

The US Fish and Wildlife Service (FWS) has restored the five-year age requirement for exported American ginseng, reversing its decision of a year ago to up the requirement to 10 years 1("The Tan Sheet," August 15, 2005, p. 12) The agency says that allowing the plant to be cut at five years "will not be detrimental to the survival of the species." The change comes as a relief to ginseng growers, who last year were disconcerted by the 10-year ruling and complained to the agency. FWA held four public meetings to get feedback from the industry in anticipation of the issuance of FWS 2006 wild American ginseng findings. Meanwhile, FWA is putting together a new outreach tool for ginseng growers and cultivators of medicinal herbs - a web page that will include information about international trade in CITES-listed medicinal plant species...

You may also be interested in...



Ginseng Export Finding May Cause “Significant” Drop In Wild Harvest – AHPA

The U.S. Department of Interior Fish & Wildlife Services' finding on the export of whole wild American ginseng will affect the entire whole-plant ginseng harvest for the next five years, says the American Herbal Products Association

National Drug Stockpiles Create ‘False Sense Of Security’

The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099473

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel